Intratumoral heterogeneity of cancer driver genomic alterations in myxoid liposarcomas
Therapies that target PIK3CA are unlikely to succeed because of its limited subclonal distribution. In contrast, the ubiquitous presence of t(12;16), t(12;22), and TERT promoter mutations across MLS tumors suggests that these are more effective therapeutic targets for future treatment strategies.
Authors
- Alexander Runkel (ORCID: https://orcid.org/0000-0002-5283-2322)
- Melanie Boerries (ORCID: https://orcid.org/0000-0002-3670-0602)
- Jurij Kiefer (ORCID: https://orcid.org/0000-0002-1008-4522)
- Adrian Schmid (ORCID: https://orcid.org/0009-0001-4018-1702)
- David Braig (ORCID: https://orcid.org/0000-0002-1267-0840)
- Thomas Pauli (ORCID: https://orcid.org/0000-0002-8381-6624)
- Laura Antolini (ORCID: https://orcid.org/0000-0003-1040-4191)
- Steffen U. Eisenhardt (ORCID: https://orcid.org/0000-0003-4471-3160)
- Peter Bronsert (ORCID: https://orcid.org/0000-0001-8558-0347)
- Ute Lausch
- Anja E. Eisenhardt (ORCID: https://orcid.org/0000-0001-6362-3828)
- Balázs Bogner (ORCID: https://orcid.org/0009-0004-8578-295X)
- Anika Boneberg
Institutions
- University of Freiburg (DE)
- University Medical Center Freiburg (DE)
Publication Details
- Journal
- Cancer
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1002/cncr.35937
- Citations
- 2
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Deutsche Forschungsgemeinschaft
- Albert-Ludwigs-Universität Freiburg